

To improve the lives of patients by creating & developing innovative antibody products



2 marketed products

DARZALEX[®] marketed in the US, Europe & other countries
Arzerra[®] marketed globally*



2 proprietary technologies

DuoBody[®] bispecific platform
HexaBody[®] technology



>20 pre-clinical projects

Extensive partnered & own pre-clinical pipeline incl. DuoBody-CD40x4-1BB



Solid financial base

Aim to own at least 50% of product rights
Allows for building capabilities to market own product in future



4 proprietary clinical programs

Tisotumab vedotin, HuMax[®]-AXL-ADC, HexaBody-DR5/DR5, DuoBody-CD3xCD20



2 categories of cancer

Generate products to treat both solid tumors & hematological cancers



3 office locations

Facilities in Denmark, the Netherlands & USA



>200 FTE

Highly experienced & skilled employees

DKK

70.8B

2016 year end market cap

DKK

763M

2016 operating expenses
32% increase versus 2015

DKK

1,816M


2016 revenue
60% increase versus 2015

DKK

3,922M

2016 year end cash position

Operating Result MDKK



2017 Guidance

Income Statement	DKKM	USDM*
Revenue	2,240 – 2,440	355 - 387
Operating expenses	(1,000) – (1,100)	(159) – (174)
Operating income	1,190 – 1,390	189 - 221
Cash position at end of year*	>4,900	>777

*Cash, cash equivalents, and marketable securities
USD 1.00 = DKK 6.3038



Our Three-pronged Strategy

Focus on core competence
Turn science into medicine
Build a profitable & successful biotech

Executive Management:

Jan G. J. van de Winkel
Ph.D. President & CEO

David A. Eatwell FCCA
Executive Vice President & CFO

Judith Klimovsky M.D.
Executive Vice President & CDO

Founded: 1999, IPO: 2000
Exchange: NASDAQ
OMX Copenhagen A/S

Symbol:
GEN

ADR ticker Symbol:
GMXY

Stock information as of January 23, 2018:

Market cap:
~DKK 69 Bn (~USD 11,401 M)
Shares outstanding:
61,185,674

*See Arzerra "At-A-Glance" on following page for additional information

Robust Product Pipeline and Passion for Innovation

Development for Marketed & Genmab Proprietary Products

Product	Disease Indications	Development Phase				
		Pre-clinical	I	I/II	II	III
Daratumumab Target: CD38, Partner: Janssen (2 – MM)	BTD Multiple myeloma (MM) Non-MM & Solid tumors					
Ofatumumab (OMB157) Target: CD20, Partner: Novartis	BTD (CLL) Follicular lymphoma (FL) Relapsing multiple sclerosis (RMS) (SubQ) Solid cancers					
Tisotumab vedotin Target: TF, Partner: Seattle Genetics						
HuMax-AXL-ADC Target: AXL	Solid cancers					
HexaBody-DR5/DR5* Target: DR5	Solid cancers					
DuoBody-CD3xCD20* Target: CD20	B-cell malignancies					

Additional Shots on Goal

Teprotumumab (RV001) Target: IGF-1R, Partner: River Vision	BTD Graves' orbitopathy					
AMG 714 Target: IL-15, Partner: Amgen	Celiac disease					
BMS-986253* (HuMax-IL8) Target: IL8, Partner: BMS	Advanced cancers					
ADCT-301 (HuMax-TAC-ADC) Target: CD25, Partner: ADCT	Lymphoma Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL)					
JNJ-61186372 Targets: EGFR, cMET, Partner: Janssen	Non-small-cell lung cancer (NSCLC)					
JNJ-63709178 Targets: CD3, CD123, Partner: Janssen	AML					
JNJ-64007957 Targets: BCMA, CD3, Partner: Janssen	Relapsed or refractory MM					
> 20 Active Pre-clinical programs incl., DuoBody-CD40x4-1BB	Proprietary programs: HuMab, HuMab-ADC, DuoBody, DuoBody-ADC & HexaBody Partnered programs: HuMab, DuoBody & HexaBody					

*Announced

This document contains forward looking statements that involve significant risks and uncertainties. Discussion of which can be found in Genmab's annual report at genmab.com. v24012018

At-A-Glance – SELECTED PRODUCTS

DARZALEX® (daratumumab)*

- First-in-class CD38 antibody in dev. to treat cancer
- Marketed as monotherapy in US & EU for double refractory MM
- Approved in US, EU & Japan in combo w/ Revlimid & dex or Velcade & dex for relapsed/refractory MM
- Approved in US in combo w/ Pomalyst & dex for pts w/ MM who have received at least 2 prior therapies
- Studies ongoing for all stages of MM & in solid tumors
- Collaboration with Janssen,
- 2017 net sales reported by Janssen; \$1,242M

Tisotumab vedotin

- Antibody-drug conjugate (ADC, antibody coupled to a cell-killing agent) in dev. to treat solid tumors
- Ph II study in various solid tumors ongoing
- Ph II clinical study in cervical cancer announced
- 50:50 co-development with Seattle Genetics

HuMax®-AXL-ADC

- ADC in development to treat solid tumors
- Ph I/II clinical study for solid tumors ongoing

Arzerra® (ofatumumab)*

- Human CD20 antibody in dev. to treat cancer & autoimmune disease
- Approved in certain territories for certain CLL indications. On January 22, 2018 it was announced that Novartis intends to transition Arzerra from commercial availability to limited availability via compassionate use programs in Non US markets.
- 2 Ph III studies w/ low dose subcutaneous in RMS ongoing
- Collaboration with Novartis

HexaBody-DR5/DR5

- Potential in solid tumors
- Ph I/II clinical study planned for 2018

DuoBody-CD3xCD20

- Potential in B-cell malignancies
- Ph I/II clinical study planned for 2018

Pre-Clinical Programs

- Broad pre-clinical pipeline of >20 programs including DuoBody-CD40x4-1BB
- Pre-clinical pipeline includes both partnered products & in-house programs based on our proprietary technologies
- Multiple INDs expected to be submitted over coming years

TECHNOLOGIES

DuoBody® Platform

- Genmab's proprietary bispecific antibody tech. platform
- Potential application in cancer, autoimmune, infectious, cardiovascular & CNS diseases
- Multiple ongoing collaborations incl. with Novo Nordisk, Gilead & Janssen Biotech

Antibody-Drug Conjugates

- Monoclonal antibodies w/ potent toxic agents coupled to them
- Expanding development area or cancer immunotherapy

HexaBody® Technology

- Genmab's proprietary enhanced potency antibody tech. platform
- Broadly applicable tech. builds on natural antibody biology
- Pre-clinical proof-of-concept achieved
- Multiple research collaborations

Antibody Generation Technology Platforms

- UltiMab transgenic mouse technology
- OmniAb transgenic mouse & rat platforms
- MAB Discovery's rabbit antibody platform

*See local country prescribing information for precise indications

Products in development, [Daratumumab](#), [Ofatumumab](#), [Tisotumab vedotin](#), [HuMax-AXL-ADC](#), [Pre-clinical programs](#), [Technologies](#)